pra023
mAbexperimental
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
9
Phase 3
3
Phase 4
0
Earliest trial started Dec 14, 2020 (NCT04676178)
Timeline
Indications
Mechanism of action
TNFSF15 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095370 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07176390 | Phase 2 | Oct 8, 2025 | Merck |
| NCT07133633 | Phase 2 | Sep 26, 2025 | Merck |
| NCT06956235 | Phase 2 | Jun 9, 2025 | Merck |
| NCT06651281 | Phase 3 | Dec 18, 2024 | Merck |
| NCT06575595 | Phase 1 | Sep 24, 2024 | Merck |
| NCT06829225 | Phase 1 | Jun 13, 2024 | Merck |
| NCT06430801 | Phase 3 | Jun 5, 2024 | Merck |
| NCT06052059 | Phase 3 | Oct 18, 2023 | Merck |
| NCT05354349 | Phase 1 | Apr 6, 2022 | Altasciences Company Inc., Merck |
| NCT05270668 | Phase 2 | Feb 22, 2022 | Merck |
| NCT05013905 | Phase 2 | Jul 28, 2021 | Prometheus Inc. |
| NCT04996797 | Phase 2 | Jul 14, 2021 | Prometheus Inc. |
| NCT04676178 | Phase 1 | Dec 14, 2020 | Celerion, Prometheus Inc. |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 10 | 10 | 3 | 2022 |
| Prometheus Inc. | For profit | 3 | 3 | 2 | 2020 |
| Altasciences Company Inc. | For profit | 1 | 0 | 1 | 2022 |
| Celerion | For profit | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1